올릭스

226950KOSDAQ자연과학 및 공학 연구개발업

43.5 / 100

Reference Date: 2026-04-13

Financial Score14.0 / 40

News Sentiment11.5 / 25

Momentum8.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, Operating Profit is on a declining trend. Plunged 15.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Olix is a biopharmaceutical company specializing in developing therapeutic drugs for difficult-to-treat diseases using RNA interference (RNAi) platform technology. The company leverages its proprietary 'self-delivering asymmetric siRNA (cp-asiRNA)' technology to create drug candidates targeting metabolic diseases, obesity, and cardiovascular conditions. Through technology licensing agreements with global and domestic pharmaceutical companies, including a significant deal with Eli Lilly, Olix has established a strong market presence and revenue streams.

Number of Employees

76people

Average Salary

198.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

—Industry Average 3.823.5Point

ROE

-18.68Industry Average -32.113.5Point

Below industry avg

Debt Ratio

15.97Industry Average 7.520.0Point

2.1x industry avg (risky)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲45.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼33.5% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -56.5% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 0Neutral 1Negative 1Average Sentiment Score 40

Neutral
바이오 액티브 ETF 봄바람…KoAct·TIME 코스닥액티브 등 '눈길...
바이오 액티브 ETF들이 활황을 보이며 코스닥 시장에서 바이오 종목에 대한 투자자들의 관심이 높아지고 있다.
Negative
올릭스, 임원 보수 규정 '부결'…남양유업 판례 '직격탄'
올릭스는 정기주주총회에서 임원 보수 규정 제정 안건이 부결되어 보수 체계 정비에 제동이 걸렸으며, 이는 대법원 판례 이후 이해관계자 의결권 제한으로 인한 정족수 미달 사례이다.

Detailed Momentum

52-week position6.0Point

52w upper range (75%)

Current 164,800Won52-week high 207,00052-week low 34,800

1-month return0.0Point

1m -15.92% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-04-01
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral주식매수선택권부여에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26
Neutral사업보고서 (2025.12)2026-03-18